Monthly Archives: November 2019

CV Sciences Inc. (OTCMKTS:CVSI) Enters Distribution Partnership With Southeastern Grocers

CV Sciences Inc. (OTCMKTS:CVSI) Enters Distribution Partnership With Southeastern Grocers

CV Sciences Inc. (OTCMKTS:CVSI) and Southeastern Grocers Inc. have announced a distribution partnership for PlusCBD Oil Topical Products as well as Dietary Supplements. The initial launch will be at the 115 Winn-Dixies in Florida and South Carolina’s 37 BI-LO stores. The PlusCBD Oil topical products have been available in the stores since November 3.

Distribution
partnership to enhance the availability of CV Sciences CBD products

The new distribution agreement between CV Sciences and
Southeastern Grocers enhances the distribution and availability of CV Sciences’
wide range of products. The broad range of products also includes ingestible
dietary supplements besides PlusCBD Oil. The new distribution in BI-LO outlets
in South Carolina and some Winn-Dixie outlets in Florida includes topical
products such as PlusCBD Oil Roll-On, and PlusCBD Oil Extra Strength and
Original Balm. There are also PlusCBD Oil full-spectrum hemp supplements such
as Gold Formula Drops and Gummies, Gold Formula as well as Total Plant Complex
Sprays.

CV Sciences CEO Joseph Dowling indicated that they are delighted to expand the distribution through the partnership with Southeastern Grocers. The agreement will enable the company to bring its topical products and dietary supplements to the mass food and retail channel. The CEO added that after the initial launch, they expect more distribution gains in Florida and Colorado.

CV Sciences
receives an award for best supplements

In September, the company indicated that it had received the “NEXTY consumer Choice Award” in the dietary supplement category for its PlusCBD Oil Total Plant Complex Peppermint Spray. The award given annually at the Natural Products Expo East and West acknowledges innovative and inspirational natural products. Products that win the award are determined through consumer feedback that sample and ward scores to the products.

The Company’s PlusCBD Oil has best-selling CBD
supplement in the Total US Natural Channel. The Extra Strength is ranked first
in sales in the Total US MULO and Total US Natural Channel alongside CBD
products in Topical Analgesics. The BD topicals market is growing fast, and
according to Brightfield Group, the market will be worth $1.3 billion this
year.

Published at Thu, 21 Nov 2019 13:05:00 +0000

Aleafia Health Launches International Medical Cannabis White Label Services

Aleafia Health Launches International Medical Cannabis White Label Services

Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) has completed production of its first white label production run of medical cannabis oils, for distribution in Australia. The cannabis oils were produced at the Company’s Paris Processing Facility and will be distributed by Melbourne, Australia based Montu Group Pty. Ltd. (“Montu Group”), leveraging their newly launched premium medical brand Circle.

The transaction represents the first production run of Aleafia Health’s newly launched international white label production service, which leverages the Company’s proven formulas and international distribution channels.

“We are pleased to leverage our established Australian sales channel and new relationship with Montu Group in this fast growing medical cannabis market. With the strength of our existing local distribution network and investments, we are increasing our Australian footprint, as we also deploy our cannabis education platform and clinic operations expertise,” said Aleafia Health CEO Geoffrey Benic. “White label production also represents a new opportunity for us and highlights the strength of our value-added production ecosystem.”

“The launch of our medical cannabis brand Circle in Australia is strengthened by Aleafia Health’s proven product expertise derived from their proprietary set of over 10 million patient-related data points,” said Montu Group Managing Director Christopher Strauch. “Australia is a core pillar of our international expansion strategy, as one of the leading and fastest growing medical cannabis markets in the world. This relationship marks an important milestone in supporting our growing network of doctors to access high quality cannabis products.”

All necessary import permits from the Australian Department of Health have been secured, and the shipment is expected to be completed in late 2019, following receipt of necessary Health Canada export permits.

Aleafia Health contact:

Nicholas Bergamini, VP Investor Relations
1-833-TSX-ALEF (879-2533)
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

Montu Group contact:

Christopher Strauch, Managing Director
Email: media@montugroup.com
Website: www.montugroup.com

About Aleafia Health:

Aleafia Health is a leading, vertically integrated cannabis health and wellness company with four primary business units: Cannabis Cultivation & Products, Health & Wellness Clinics, Cannabis Education, and Consumer Experience with ecommerce, retail distribution and provincial supply agreements.

Aleafia Health owns three major cannabis product & cultivation facilities, two of which are licensed and operational including the first large-scale, operational outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.

About Montu Group:

Montu Group is a leading medical cannabis company with operations in Europe and Asia-Pacific. The company facilitates access to medical cannabis through education, quality products, and personalised service. Montu Group offers its premium Circle range of high-quality medical cannabis products to a growing network of doctors and pharmacists. The team has built trusted clinical support structures and forged strong relationships with the medical community, in line with its commitment to improve the lives of millions of patients, as laws and regulations evolve across international markets.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Primary Logo

Published at Thu, 28 Nov 2019 14:17:05 +0000

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) And STENOCARE Sign An MOU

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) And STENOCARE Sign An MOU

OWC
Pharmaceutical Research Corp (OTCMKTS:OWCP)

and STENOCARE are into a new progressive deal. The two business giants just
moved into a Memorandum of Understanding (MoU) that is quite strategic. These
two seek to engage in the development and the commercialization of some
wide-ranging cannabis-based medical products.

Terms of
the deal

Each of the parties will have something to gain
from the deal. For instance, OWC’s technologies will benefit from a more
expansive market. On the other hand, the business strategy of STENOCARE might
end up becoming a huge success. The business guru has been looking forward to
supplementing its top-quality generic medical cannabis products. Its target has
been to supplement them with differentiated products meant to treat numerous
patient groups struggling with particular serious conditions.

The new cooperation means well for them, considering
that they will increase their sales massively. They will also be able to
distribute products in large volumes within the existing core markets of
STENOCARE. The businesses also want to venture into new territories in their
quest to boost their business profits.

STENOCARE
and its plans

STENOCARE expresses its willingness to deliver some
top quality cannabis raw materials. Asides from that, it will also be seeking
to provide extensive knowledge in line with the supply and the distribution of
the medical cannabis-based products in Ireland and Denmark as well.

On the other hand, OWC Pharmaceutical says it will
offer its expertise in clinical trials and medical research. The business has
been focusing on cannabis products providing therapeutic solutions to patients.
It prides itself on having in place what it terms an extensive Intellectual
Property Portfolio.

The first
product candidate

The information regarding the first product
candidate for this collaboration is already out. This will be a sublingual tablet
pulling along with specified medical cannabis ratios vital in meeting up to the
needs of patients. It will be important to make the appropriate diagnosis as
well as check out how they will be responding to treatment.

The CEO of OWC Pharmaceutical Research Mordechai
Bignitz says that STENOCARE is a great choice for a partner. He says that
considering the company’s capacity in the distribution of medical cannabis
products to some interesting markets. This official also speaks about the focus
on pharma-grade production.

Published at Mon, 25 Nov 2019 13:01:00 +0000

The Economics of Cannabis

The Economics of Cannabis

The economics of cannabis could not be simpler. All it takes is to first spend a few moments thinking.

Thanks to nearly a century of cannabis Prohibition, the legal cannabis industry is artificially beginning from scratch.

Thanks to nearly a century of cannabis Prohibition, the cannabis black market is an efficient, well-established, multi-billion dollar enterprise.

Everyone agrees (except for the waning population of anti-cannabis dinosaurs) that it is desirable for the legal cannabis industry to absorb/phase-out the black market. Everyone agrees that it is desirable for this transition to take place as quickly as possible.

Therefore, the legal cannabis industry requires a regulatory structure that will make it fully competitive with the cannabis black market.

Simple.

A recent article from Canada’s CBC attempted to make this point.
 

Only governments can solve the Canadian illicit pot crisis

Economists told governments how to wipe out the black market. They didn’t listen. 

Right idea. Poor way of framing it.

Economists (with rare exceptions) are dim-witted ivory tower clods. A 20-year academic study of the forecasting of such “experts” found their accuracy was only marginally better than a dart-throwing chimp.

What the CBC should have said is this. The economics of cannabis are so simple and obvious that even an economist can understand it.
 

While the legal industry battles to grab market share from their illicit competitors, economists could have told them this would happen.

And not just “could have.” Economists did tell them. In April 2017, long before cannabis became legal on Oct. 17, 2018, economist Rosalie Wyonch, a policy analyst with the C.D. Howe Institute, was one of those who had a warning for governments expecting to get rich from legalized pot.

“If the government taxes marijuana heavily,” she wrote in an open letter to Bill Blair, the federal cabinet minister who led the way on Canada’s pot policy, “it will ensure the continuation of the black market and will be undermining its efforts to control the substance.”

Despite this simple and obvious Big Picture, the legal cannabis industry in North America continues to be dysfunctional (to be polite).

In Canada, the cannabis black market still reaps roughly 85% of cannabis revenues. In California, the cannabis black market has actually grown larger since full legalization at the start of 2018.

Why? Because residual ignorance and anti-cannabis biases continue to linger at the political level. Common sense is almost non-existent.

This results in politicians continually undermining rather than assisting the legal cannabis industry in displacing the black market.

At both the national and state/provincial level, (most) governments are strangling the legal cannabis industry with red tape: procedural hurdles, compliance issues, security checks.

The black market wins.

At both the national and state/provincial level, governments are then burdening the legal cannabis industry with additional taxes and fees – making it impossible to be price-competitive.

The black market wins.

At the state/provincial level, governments then refuse to provide consumers with reasonable access to legal cannabis. This comes through foolishly allowing local governments to ban legal cannabis businesses (California), or simply failing to open a reasonable number of retail cannabis stores (Ontario).

Restricting the number of cannabis retail outlets or just refusing to license any legal cannabis businesses accomplishes only one thing: crippling the legal cannabis industry.

The black market wins.

In the tiny, propaganda-warped minds of the politicians, they are still “protecting us” from cannabis. Case in point, Canada’s clueless pot czar, Bill Blair.
 

“It’s not the government’s intention to promote the use of this drug but rather to make it legally available in a well-regulated manner to reduce the social and health harms often associated with cannabis use.”  [emphasis mine]

The supposed “social and health harms” that Blair claims are “often associated with cannabis use” are non-existent. Just anti-cannabis propaganda.

Cannabis is non-toxic and non-addictive. No one has ever died from a cannabis overdose. Cannabinoids are produced naturally in the human body and are essential to human health.

The only “harm” that has ever been “associated” with cannabis is the black market that our governments created when they needlessly criminalized cannabis.

Canadians don’t need to protected from cannabis. They only need to be protected from the stupidity and corruption of their political leaders with respect to cannabis laws.

Sensible governments should “promote the use” of cannabis as a much safer alternative to alcohol and/or tobacco products. It could save billions of dollars each year in healthcare costs, not to mention the savings in human lives.

Instead, idiot-politicians in Canada refuse to allow the cannabis industry to advertise, hiding it from consumers. They create ridiculous “potency limits” for cannabis products that have no scientific basis.

The federal government taxes medicinal cannabis, providing an economic incentive for Canadians to purchase their medicine from the black market. Then Health Canada has a hissy-fit when a Canadian LP is discovered supplying cannabis to the same black market.

Quebec’s provincial government has gone even farther with its irrational anti-cannabis paranoia.

The provincial government recently raised the legal age for cannabis consumption from 18 to 21. This won’t stop young adults in Quebec from purchasing and consuming cannabis. It will simply force them to buy their cannabis illegally.

In Ontario, the provincial government spends half its time discovering new ways to lose taxpayer dollars on legal cannabis. And it spends the other half of its time thinking up new excuses and delays in opening retail cannabis stores.

The situation is even worse in the United States.

In the Land of Anti-Cannabis Idiots, cannabis is still legally equated with heroin at the federal level. As a direct result of this regulatory vacuum, thousands of Americans have become ill and dozens have died from tainted black market cannabis vaping products.

Is Congress fast-tracking national cannabis legalization so that the federal government can fill this regulatory vacuum and nationally regulate/inspect cannabis consumer products as soon as possible?

No.

The Democrats just voted on a partisan bill in the House that they are calling “marijuana legalization” (U.S. politicians have a mental block that prevents them from saying the word “cannabis”).

It’s not legalization. It’s merely cannabis decriminalization. All that decriminalization would do is to allow the cannabis black market to get much larger. More Americans would be exposed to tainted vaping products.

And this partisan bill has absolutely zero chance of making it through the Senate.

The Republicans? They are doing nothing at all.

At the state level, governments are reluctantly legalizing cannabis – generally only when forced to do so by voter ballot. Then state politicians (cowardly) allow local governments to “opt out” of cannabis legalization.

Understand the monumental stupidity here.

Thanks to the enormous cannabis black market created by our governments, local governments can’t “ban cannabis”. They can only ban legal cannabis – and thus preserve that jurisdiction for the black market.

Even an economist can understand that.

Cannabis use is not merely safe, it is healthy. The cannabis plant is without question the world’s most commercially versatile crop, especially once the hemp sub-species is factored into the equation.

Our leaders should be bending over backwards to support the legal cannabis industry – for the potential tax revenues alone (from moderate taxation). Instead, they continue to undermine the legal industry at every turn.

The economics of cannabis is simple.
 

a)  Support the legal cannabis industry.
b)  Phase-out the black market.
c)  Collect tax dollars.

By refusing to do (a), the politicians are failing to do (b), and throwing away (c).
 

Published at Fri, 22 Nov 2019 20:33:19 +0000

HTC Announces Acquisition of California-Based Kase Farma Inc.

HTC Announces Acquisition of California-Based Kase Farma Inc.

REGINA, Saskatchewan, Nov. 22, 2019 (GLOBE NEWSWIRE) — via NetworkWire — PRESS RELEASE — HTC Extraction Systems has announced that it has entered into a share and purchase agreement dated Nov. 21, 2019 with Starling Brands Inc., a party at arm’s length to HTC. Pursuant to the SPA, HTC will acquire all the issued and outstanding shares of Kase Farma Inc., a subsidiary of Starling, and upon completion of the acquisition, Kase Farma will be a wholly owned subsidiary of HTC.

Kase Farma is authorized to operate in the areas of hemp cultivation, extraction, refining, formulation and distribution in the State of California. Kase Farma continually strives to deliver health and wellness benefits of CBD, CBG, CBN and other cannabinoids via the production of high-quality, premium hemp products through best of class methods while sustaining an unrelenting commitment to people, community and the environment.

An intrinsic part of the transaction is a management services agreement with Starling, led by Mike Reynolds, chief executive officer, and Drew Ford, chief science officer, both of whom are highly regarded experts in the cannabinoid extraction, formulation and refining world. The combination of their expertise and leadership is integral to driving the success of this transaction.

“On behalf of Starling, we are extremely excited to integrate our experience, know how and pedigree with HTC’s technologies and pedigree to further the vision and execution as global leaders in the science and production of the highest quality cannabinoid extractions and formulations,” Reynolds said. “The benefits that will be provided to the global community are consistent with the irreversible momentum of changing perceptions and acceptance of the planet’s most useful and beneficial plant.”

Pursuant to the SPA, HTC will acquire the purchased shares in exchange for US$900,000 in cash and the issuance of 8,000,000 units of HTC and 2,000,000 bonus units of HTC. Each unit will consist of one common share and one half of one common share purchase warrant of HTC. Each warrant shall be exercisable to acquire one common share at a price of C$0.70 for a period of 36 months from the completion of the transaction. Each bonus unit will consist of one common share and one half of one common share bonus purchase warrant of HTC. Each bonus warrant shall be exercisable to acquire one common share at a price of C$1.00 for a period of 36 months from the completion of the transaction. In addition, the units and bonus units shall be subject to legends restricting their transfer and which will provide that: (i) one-third of the compensation units shall become freely tradeable on the date that is 12 months following the completion of the transaction; (ii) one-third of the compensation units shall become freely tradeable on the date that is 18 months following the completion of the transaction; and (iii) one-third of the compensation units shall become freely tradeable on the date that is 24 months following the completion of the transaction.

In December, Kase Farma, will receive and commission equipment that’s able to process and distill 12,000 lbs. per day of dried biomass at its “IPElite Extraction” operation in California. Kase Farma’s “IPElite Extraction” operations are part of the vendor-owned 22,000-square-foot overall facility and will process 12,000 lbs. per day of dried biomass; which, at an 8% CBD yield, will have the capability of producing, 435,000 grams daily of CBD, delivering highest quality, saleable CBD to the wholesale market with gross revenue potential of approximately $1.4 million USD per day.

Kase Farma also intends to build a 20,000-square-foot facility in the fall of 2020, which will have the capability to extract, refine, and formulate cannabinoids for an additional 50,000 lbs. per day of dried biomass capacity for HTC’s emerging global food and drink CBD ingredient market.

Kase Farma has launched its Identity Preserved, or IPGrow, initiative, with the intention of providing the consumer with full transparency as to where their products have come from and how they were produced, bringing accountability and verified quality to the cannabinoid industry. Kase Farma has aligned itself with highly regarded hemp growers in California’s Central Valley who will provide up to 15,000 acres of high performance, IPGrow, superior, genetic specific production for its custom designed cannabinoid formulations.

Kase Farma will continue to build on its pedigree, quality and industry recognized expertise through a partnership with Kase Manufacturing Inc., a Ceres, California-based wholly owned subsidiary of Starling. Kase Manufacturing is driven by quality, integrity and innovation, managed by a world-class team of experts with over 50 years of combined experience, and will integrate this experience to help accelerate the growth and success of Kase Farma and HTC. Kase Manufacturing is one of the first volatile and non-volatile cannabinoid extraction manufacturing labs approved in the State of California. Kase Manufacturing utilizes the highest-quality extraction and refining equipment and laboratory tools available today and is operated by an award-winning team of extractors and formulators, who consistently produce industry best cannabinoid oils and distillate.

Kase Manufacturing, under Starling Brands, is licensed to operate in the areas of cannabis extraction, refining, formulation and distribution in the State of California. As part of the Transaction, Kase Farma will enter into an intellectual property licensing agreement with Starling that will allow for a technology transfer whereby intellectual property and technology licensed under this agreement will be utilized and deployed in HTC’s Canadian facility.

Reynolds has spent the last 10 years building political, business and community alliances in the cities of Ceres and Modesto, California. His involvement in cannabinoids began after his son, Kase, was diagnosed with epilepsy at the age of four months. Mike then formed a partnership with Jason David whose son also suffered from epilepsy, which gave a new impetus to the development and success of the Jayden’s Juice product offer, a cannabinoid-rich tincture, manufactured by Kase Manufacturing.

Reynolds directed the planning, design, construction, licensing, and staffing of Kase Manufacturing, one of the first cannabinoid manufacturing labs approved for operations in the State of California. His hands-on experience as a pioneering developer of medicinal cannabinoid products gives him the foresight that will allow Kase Farma to adapt quickly to changes in the hemp CBD, CBG and CBN marketplace. His relationship with the City of Ceres and experience as a parent of a child whose life was transformed by medicinal cannabinoids are invaluable to Kase Farma’s success.

Drew Ford has previously worked as a chemical engineer in the reverse osmosis desalination industry, working in research and development and chemical purification before making the switch to the cannabinoid space. Ford’s experience and passion for chemical purification and refinement brought him to the cannabinoid market. He was a key member of the team that developed the first vacuum distillation process equipment for cannabinoid oil and has optimized and redefined the standard of “potency” and “efficacy.” Many of the wiped film refining systems today being offered by equipment OEMs enshrined Ford’s significant experience in vacuum distillation product enhancement.

The transaction remains subject to customary closing conditions, including approval of the TSX Venture Exchange and is expected to be completed in December of this year.

Published at Fri, 22 Nov 2019 16:31:00 +0000

House Committee Approves Bill to End Federal Cannabis Prohibition, Michigan Issues First Adult-Use Cannabis Licenses: Week in Review

House Committee Approves Bill to End Federal Cannabis Prohibition, Michigan Issues First Adult-Use Cannabis Licenses: Week in Review

REGINA, Saskatchewan, Nov. 22, 2019 (GLOBE NEWSWIRE) — via NetworkWire — PRESS RELEASE — HTC Extraction Systems has announced that it has entered into a share and purchase agreement dated Nov. 21, 2019 with Starling Brands Inc., a party at arm’s length to HTC. Pursuant to the SPA, HTC will acquire all the issued and outstanding shares of Kase Farma Inc., a subsidiary of Starling, and upon completion of the acquisition, Kase Farma will be a wholly owned subsidiary of HTC.

Kase Farma is authorized to operate in the areas of hemp cultivation, extraction, refining, formulation and distribution in the State of California. Kase Farma continually strives to deliver health and wellness benefits of CBD, CBG, CBN and other cannabinoids via the production of high-quality, premium hemp products through best of class methods while sustaining an unrelenting commitment to people, community and the environment.

An intrinsic part of the transaction is a management services agreement with Starling, led by Mike Reynolds, chief executive officer, and Drew Ford, chief science officer, both of whom are highly regarded experts in the cannabinoid extraction, formulation and refining world. The combination of their expertise and leadership is integral to driving the success of this transaction.

“On behalf of Starling, we are extremely excited to integrate our experience, know how and pedigree with HTC’s technologies and pedigree to further the vision and execution as global leaders in the science and production of the highest quality cannabinoid extractions and formulations,” Reynolds said. “The benefits that will be provided to the global community are consistent with the irreversible momentum of changing perceptions and acceptance of the planet’s most useful and beneficial plant.”

Pursuant to the SPA, HTC will acquire the purchased shares in exchange for US$900,000 in cash and the issuance of 8,000,000 units of HTC and 2,000,000 bonus units of HTC. Each unit will consist of one common share and one half of one common share purchase warrant of HTC. Each warrant shall be exercisable to acquire one common share at a price of C$0.70 for a period of 36 months from the completion of the transaction. Each bonus unit will consist of one common share and one half of one common share bonus purchase warrant of HTC. Each bonus warrant shall be exercisable to acquire one common share at a price of C$1.00 for a period of 36 months from the completion of the transaction. In addition, the units and bonus units shall be subject to legends restricting their transfer and which will provide that: (i) one-third of the compensation units shall become freely tradeable on the date that is 12 months following the completion of the transaction; (ii) one-third of the compensation units shall become freely tradeable on the date that is 18 months following the completion of the transaction; and (iii) one-third of the compensation units shall become freely tradeable on the date that is 24 months following the completion of the transaction.

In December, Kase Farma, will receive and commission equipment that’s able to process and distill 12,000 lbs. per day of dried biomass at its “IPElite Extraction” operation in California. Kase Farma’s “IPElite Extraction” operations are part of the vendor-owned 22,000-square-foot overall facility and will process 12,000 lbs. per day of dried biomass; which, at an 8% CBD yield, will have the capability of producing, 435,000 grams daily of CBD, delivering highest quality, saleable CBD to the wholesale market with gross revenue potential of approximately $1.4 million USD per day.

Kase Farma also intends to build a 20,000-square-foot facility in the fall of 2020, which will have the capability to extract, refine, and formulate cannabinoids for an additional 50,000 lbs. per day of dried biomass capacity for HTC’s emerging global food and drink CBD ingredient market.

Kase Farma has launched its Identity Preserved, or IPGrow, initiative, with the intention of providing the consumer with full transparency as to where their products have come from and how they were produced, bringing accountability and verified quality to the cannabinoid industry. Kase Farma has aligned itself with highly regarded hemp growers in California’s Central Valley who will provide up to 15,000 acres of high performance, IPGrow, superior, genetic specific production for its custom designed cannabinoid formulations.

Kase Farma will continue to build on its pedigree, quality and industry recognized expertise through a partnership with Kase Manufacturing Inc., a Ceres, California-based wholly owned subsidiary of Starling. Kase Manufacturing is driven by quality, integrity and innovation, managed by a world-class team of experts with over 50 years of combined experience, and will integrate this experience to help accelerate the growth and success of Kase Farma and HTC. Kase Manufacturing is one of the first volatile and non-volatile cannabinoid extraction manufacturing labs approved in the State of California. Kase Manufacturing utilizes the highest-quality extraction and refining equipment and laboratory tools available today and is operated by an award-winning team of extractors and formulators, who consistently produce industry best cannabinoid oils and distillate.

Kase Manufacturing, under Starling Brands, is licensed to operate in the areas of cannabis extraction, refining, formulation and distribution in the State of California. As part of the Transaction, Kase Farma will enter into an intellectual property licensing agreement with Starling that will allow for a technology transfer whereby intellectual property and technology licensed under this agreement will be utilized and deployed in HTC’s Canadian facility.

Reynolds has spent the last 10 years building political, business and community alliances in the cities of Ceres and Modesto, California. His involvement in cannabinoids began after his son, Kase, was diagnosed with epilepsy at the age of four months. Mike then formed a partnership with Jason David whose son also suffered from epilepsy, which gave a new impetus to the development and success of the Jayden’s Juice product offer, a cannabinoid-rich tincture, manufactured by Kase Manufacturing.

Reynolds directed the planning, design, construction, licensing, and staffing of Kase Manufacturing, one of the first cannabinoid manufacturing labs approved for operations in the State of California. His hands-on experience as a pioneering developer of medicinal cannabinoid products gives him the foresight that will allow Kase Farma to adapt quickly to changes in the hemp CBD, CBG and CBN marketplace. His relationship with the City of Ceres and experience as a parent of a child whose life was transformed by medicinal cannabinoids are invaluable to Kase Farma’s success.

Drew Ford has previously worked as a chemical engineer in the reverse osmosis desalination industry, working in research and development and chemical purification before making the switch to the cannabinoid space. Ford’s experience and passion for chemical purification and refinement brought him to the cannabinoid market. He was a key member of the team that developed the first vacuum distillation process equipment for cannabinoid oil and has optimized and redefined the standard of “potency” and “efficacy.” Many of the wiped film refining systems today being offered by equipment OEMs enshrined Ford’s significant experience in vacuum distillation product enhancement.

The transaction remains subject to customary closing conditions, including approval of the TSX Venture Exchange and is expected to be completed in December of this year.

Published at Sat, 23 Nov 2019 11:00:00 +0000

The Billion Dollar Asian CBD Market Is Ripe For The Taking

The Billion Dollar Asian CBD Market Is Ripe For The Taking

During the last year, we saw increased interest in the cannabidiol (CBD) vertical of the cannabis industry and this comes after the US legalized the high-value cannabinoid in late 2018.

Demand for CBD products continues to increase as researchers learn more about the benefits associated with the cannabinoid. We believe that researchers still have a lot to learn when it comes to CBD and expect to see increasing demand for products that contain the high-value cannabinoid.

Although we are excited about the growth prospects associated with the burgeoning CBD opportunity, several of the most exciting markets are saturated and very competitive. For this reason, we have been focused on identifying markets that are still in their infancy when it comes to the CBD opportunity.

Asia is a market that we have been excited about and believe that the opportunity is much less saturated when compared to North America and Europe. Very few countries in Asia have legalized any form of cannabis (CBD or medical cannabis) and we expect to see new markets open in the near future.

According to Prohibition Partners, Asia’s cannabis market is estimated to be worth more than US$5.8 billion by 2024. Also, China in particular has a potential US$4.4bn market size for CBD products and already places no limitation on CBD content for its cosmetics. From a population standpoint, Asia represents the largest market in the world and we are favorable on this aspect of the story. In 2020, we expect to see the Asian CBD market to record substantial growth and this is a trend that we expect to continue on a going forward basis. We have been increasingly interested in companies that are levered to the Asian CBD market and want to highlight an opportunity that we recently started to cover.

The company, Canrim Growth Group represents an attractive play on the Asian CBD market and we believe that the business is well positioned to capitalize on this emerging opportunity. The company has an attractive operating structure and is led by a management team that has been nothing short of a success story in the Asian market.

Plans to Capture Market Share in the World’s Largest Market

When it comes to Canrim, one of the first characteristics to stand out is related to the operating structure. The company is comprised of two portfolio companies, CBD Group Asia (CGA) and Natural Source Group (NSG), that provide direct exposure to strategic Asian markets (China, Hong Kong, Singapore, and Thailand). We are favorable on the structure of the operation as well as on the amount of value that these two divisions can create for the business.

CGA is a distribution and investment company that has been focused on China’s CBD market. Earlier this year, the companies entered into an investment agreement for Canrim to fund and earn up to a 75% ownership in CGA. Through its incubation program in Shanghai, CGA is investing and partnering with CBD related start-ups and established businesses in the region to create new brands and introduce high tech solutions within the CBD sector. This strategy provides CGA with the opportunity to work with early stage as well as advanced businesses that are levered to the CBD industry and we are favorable on the amount of value that can be created through this.

One of the most important aspects of the CGA opportunity is related to its expanding distribution network and we are favorable on the leverage that Canrim will have to it. CGA has already secured strategic partnerships with successful North American brands for introduction of their product line into the Asian marketplace through their China focused distribution partners. Distribution is one of the most important aspects of the CBD industry and we are favorable on how this asset enhances the Canrim story.

With regard to NSG, Canrim has an exclusive, commercial arrangement to distribute co-branded CBD products across NSG’s platform. NSG has an Asia-wide distribution reach which has been conducting sales since 2013. NSG’s underlying investment thesis is that a fundamental imbalance exists between sources of supply and aggregate demand in areas of the emerging frontiers of Asia. We will monitor how the two teams are able to work together and create value for the entire business. We are favorable on the skills that NSG and Canrim bring to the relationship and will keep an eye on this aspect of the story.

An Emerging Opportunity that is on our Radar

We believe that Canrim represents a differentiated opportunity and are favorable on the way the management team is approaching the CBD market. Over the next year, we expect to see the company enter new markets and improve its influence to a market that is not saturated and which that has substantial growth prospects.

Canrim is acting as a pioneer for Asia-centric CBD business development and is well positioned to be a key player in the investment, distribution and marketing of CBD-rich health products. The company is led by a management team that is comprised of international business and capital markets experts who are committed to executing on an aggressive, cost-effective growth strategy.

When looking at the people who make up Canrim’s management team, there is a lot to be excited about. Canrim Growth Group CEO Ranjeet Sundher played a key role in bringing Jushi Holdings, a leading US cannabis company, to market and we are favorable on the expertise that he brings to the operation.

CBD Group Asia’s principals boast over ten years’ experience specializing in the importation and customization of premium Canadian consumer packaged goods (“CPGs”) for the Chinese marketplace. CBD Group Asia’s management team previously distributed premium Canadian CPGs into China’s largest retail chains and C-stores, including RT-Mart International Ltd and Carrefour SA. We are favorable on the people who make up the Canrim team and find this to be an important aspect of the story.

In the near future, Canrim plans to complete a go-public transaction and list on the Canadian Stock Exchange. We believe that this is an opportunity that the market needs to be aware of and we will keep an eye on how the management team continues to drive the story forward. To learn more about this opportunity, please send an email to support@technical420.com to be added to our distribution list.

Pursuant to an agreement between StoneBridge Partners LLC and Brigadier Gold Limited (BRG-H.V) we have been hired for a period of 180 days beginning September 16, 2019 and ending March 16, 2020 to publicly disseminate information about (BRG-H.V) including on the Website and other media including Facebook and Twitter. We are being paid $10,000 per month (BRG-H.V) for or were paid “0” shares of restricted common shares. We own zero shares of (BRG-H.V), which we purchased in the open market. We plan to sell the “ZERO” shares of (BRG-H.V) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (BRG-H.V) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Fri, 22 Nov 2019 12:43:07 +0000

WeedMD to Host Third Quarter 2019 Earnings Conference Call on November 29 at 10 a.m. Eastern Time

WeedMD to Host Third Quarter 2019 Earnings Conference Call on November 29 at 10 a.m. Eastern Time

WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to confirm that it will release its quarterly financials after market close on Thursday November 28, 2019. The Company will host a conference call with management on Friday, November 29, 2019 at 10 a.m. Eastern Time to report its financial results for the three- and nine-months period ending September 30, 2019, as well as provide an operational and corporate outlook. The call will be hosted by Keith Merker, CEO and Nichola Thompson, CFO of WeedMD.

Management will be available for analyst and media questions following opening remarks.

Conference Call Details:

Date: Friday, November 29, 2019
Time: 10 a.m. Eastern Time
Dial-in Number: Canada/USA: 1-800-319-4610. International Toll: 1-604-638-5340
Participants, please dial in and ask to join the WeedMD call.
Replay Dial-in: Canada/USA: 1-800-319-6413. International Toll: 1-604-638-9010
Replay Access Code: 3858
Replay will be available after 12:00 p.m. Eastern Time, until December 29, 2019.

Access WeedMD’s investor presentation here and 2019 corporate video highlights here.

About WeedMD Inc.

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer of cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, Ontario. WeedMD also operates CX Industries Inc., a wholly-owned subsidiary of WeedMD Inc. CX Industries operates out of the Company’s fully-licensed 26,000 sq. ft. Aylmer, Ontario production facility which specializes in cannabis extraction and processing. WeedMD has a multi-channeled distribution strategy that includes selling directly to medical patients, strategic relationships across the seniors’ market and supply agreements with Shoppers Drug Mart as well as six provincial distribution agencies where WeedMD’s adult-use brand Color Cannabis is sold.
Follow WeedMD & Color Cannabis: 

facebook, linkedin, twitter, instagram instagram

For further information, please contact WeedMD Inc.:

For Investor Inquiries:
James Williams
Director, Capital Markets
Email: investor@weedmd.com

For Media Inquiries:
Marianella delaBarrera
VP, Communications & Corporate Affairs
Tel: 416-897-6644
Email: marianella@weedmd.com
To learn more, visit us at www.weedmd.com

Forward Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation which are based upon WeedMD’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.

The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future growing capacity and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of WeedMD to implement its business strategies; competition; crop failure; and other risks.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD’s Annual Information Form dated June 21, 2019 (the “AIF”) and other disclosure documents of WeedMD filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the AIF and other disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

Primary Logo

Published at Fri, 22 Nov 2019 12:48:54 +0000

Future Farm Prepares Maine-Grown Hemp Biomass and Seeds for Processing and Market

Future Farm Prepares Maine-Grown Hemp Biomass and Seeds for Processing and Market

Future Farm Technologies Inc. (CSE: FFT) (OTCQB: FFRMF) is pleased to announce that it has completed the drying and curing phase of its crop of hemp and seeds in Maine. Both crops achieved yields that outpace the Company’s current apparatus for seed extraction, plant bucking, processing and storage.

To address the success of this year’s harvest, Future Farm is in the process of acquiring more robust seed extraction and cleaning equipment, additional resources for storage and transportation and larger industrial scales.

“These early findings are great news for us and as we look to meet the needs of our robust pipeline of carefully curated and diverse customers,” comments William Gildea, CEO of Future Farm. “The abundance of product enables us to service the demand for seeds, biomass, oils, extracts and contract manufacturing.”

For further information, contact Investor Relations at investor@futurefarmtech.com or (888) 387-3761 ext. 710.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman and CEO

About Future Farm Technologies Inc. 

Future Farm Technologies is a Canadian public company that is poised to be a leading supplier of hemp-derived CBD products to meet the burgeoning demand in the U.S. and global markets. The Company’s current key initiatives are the cultivation and processing of its hemp crop growing in Maine, the pursuit of other hemp-related opportunities throughout the U.S. and the development of elite strains of cannabis in Canada.

Future Farm’s seasoned management team brings a deep understanding of operations and agriculture with the financial and regulatory expertise needed to become an industry leader in the evolving market for CBD and related compounds.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Investor Relations
888-387-3761 x710
investor@futurefarmtech.com
Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Fri, 22 Nov 2019 13:30:33 +0000

Puration Inc. (OTCMKTS:PURA) Finalizes Acquisition To Bring Bottling of CBD Beverage to Europe

Puration Inc. (OTCMKTS:PURA) Finalizes Acquisition To Bring Bottling of CBD Beverage to Europe

Puration Inc.
(OTCMKTS:PURA)
has announced that it has finalized
the acquisition of a Germany company. This will enable Puration to bottle its
CBD drinks locally and supply them throughout Europe.

Puration takes
EVERx CBD Sports Water to Europe

The acquisition comes at the back of Puration, entering
a distribution agreement to supply its EVERx CBD Sports water and other
beverages in Europe. The distribution agreement will add approximately $4
million in sales in 2020.according to the management, the European market is
huge, and the sales projection needed the establishment of a local bottling
capacity.

By 2023 the CBD market in Europe will be around $17 billion. The expansion to Europe is part of the company’s strategy to expand the bottling of beverages outside Latin America and Canada. The company has indicated that it will close the acquisition on November 14.

The company has already started marketing the EVERx CBD
Sports Water in Europe. The company launched the beverage at the Arnold
Schwarzenegger Sports Festival In Barcelona. The water was introduced first in
2017 at the Arnold Classic in Ohio in 2017. It has grown to be part of the
global Arnold Sports Festival events.

EVERx Sports Water is a leading CBD infused beverage that is growing sales rapidly. In the first half of this year, the company generated sales of $1 million from the water, and it is targeting sales of around $4 million by the end of 2019. This will be different from the current anticipated $4 million from the distribution agreement.

Puration
Announces LOI for an acquisition in Latin America

Besides the acquisition in German, the company also announced a possible acquisition in Latin America same as that of Germany. The acquisition is designed to enhance foothold for the company to bottle the CBD infused beverages locally in Latin America. The Latin America CBD market is budding, and it is showing signs of massive potential. By 2028 it is estimated that the market will hit $9 billion.

Published at Fri, 22 Nov 2019 13:05:11 +0000